Mutations in KEAP1, which have a frequency of 15–18% in NSCLC, produce constitutive activation of NRF2, leading to cellular resistance to oxidative stress, proliferation, and metabolic reprogramming [137]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.